Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their ...

December 4, 2025 Amsterdam, the Netherlands ? Royal Philips , a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the ...

Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage therapeutics company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that ...

Insulet Corporation PODD reported third-quarter 2025 adjusted earnings per share (EPS) of $1.24, up 37.8% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 9 ...

Insulet has appointed Cristal Downing as chief corporate affairs officer, effective Monday, December 8. Downing will report to Ashley McEvoy, president and CEO at Insulet, a medical device company ...

Insulet (Nasdaq:PODD) announced today that it received FDA 510(k) clearance for new enhancements to its Omnipod 5 system.

Since May 2025, Insulet has been in a holding pattern, posting a small return of 3% while floating around $335.74. The stock ...

The US FDA has cleared the first updates to the algorithm of the Omnipod 5 automated insulin delivery (AID) system (Insulet ...

The FDA cleared an updated algorithm for a hybrid closed-loop insulin delivery system that permits users to set a lower ...

Insulet anticipates that the Omnipod 5 algorithm update will launch in the US in H1 2026. The company highlighted that the ...